In mouse models injected with mouse oral cancer cells, high-dose hypofractionated radiation preserves or enhances anti-tumor immunity and, when combined with anti-PD-1 monoclonal antibodies to reverse adaptive immune resistance, promotes CD8+ cell-dependent primary and abscopal tumor control [33]. This evidence concerns the gene CD8A and lip and oral cavity carcinoma.